Article
Greater uptake, education needed to realize cost-saving potential of biosimilars
Rating:
0.0
Views:
81
Likes:
1
Library:
1
Hemonc Today | More than 5 years after the first FDA approval of a biosimilar, the U.S. health care system has yet to realize the full potential of these products to reduce drug costs and increase access to hematology/oncology treatments.Biosimilars receive FDA approval after demonstrating no clinically meaningful differences in efficacy and safety compared with their patent-lapsed reference products. Because
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value